UB Paderborn / Katalog / Suche / in CDI

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The Lancet (British edition), 2006-11, Vol.368 (9548), p.1696-1705

2006

Link zum Volltext

Verfügbarkeit prüfen

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Diabetes (New York, N.Y.), 2019-05, Vol.68 (5), p.897-900

2019

Link zum Volltext

Verfügbarkeit prüfen

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

Diabetes (New York, N.Y.), 2011-05, Vol.60 (5), p.1561-1565

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

Diabetes (New York, N.Y.), 2014-02, Vol.63 (2), p.785-790

2014

Link zum Volltext

Verfügbarkeit prüfen

Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes

Diabetes (New York, N.Y.), 2004-12, Vol.53 (suppl 3), p.S190-S196

2004

Link zum Volltext

Verfügbarkeit prüfen

Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists

The Lancet (British edition), 2023-08, Vol.402 (10400), p.429-431

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Link zum Volltext

Verfügbarkeit prüfen

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

Diabetes (New York, N.Y.), 2010-05, Vol.59 (5), p.1117-1125

2010

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

American journal of physiology: endocrinology and metabolism, 1997-11, Vol.273 (5), p.E981-E988

1997

Link zum Volltext

Verfügbarkeit prüfen

Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects

Diabetes (New York, N.Y.), 2005-07, Vol.54 (7), p.2212-2218

2005

Link zum Volltext

Verfügbarkeit prüfen

342-P: Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin Glargine

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects

Diabetes (New York, N.Y.), 2004-12, Vol.53 (suppl 3), p.S220-224

2004

Link zum Volltext

Verfügbarkeit prüfen

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

European journal of endocrinology, 2019-12, Vol.181 (6), p.R211

2019

Link zum Volltext

Verfügbarkeit prüfen

Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability

Journal of diabetes science and technology, 2021-11, Vol.15 (6), p.1262-1272

2021

Link zum Volltext

Verfügbarkeit prüfen

Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)

Journal of diabetes science and technology, 2021-03, Vol.15 (2), p.360-370

2021

Link zum Volltext

Verfügbarkeit prüfen

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

The American journal of cardiology, 2018-06, Vol.121 (12), p.1467-1470

2018

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy

Journal of diabetes science and technology, 2021-11, Vol.15 (6), p.1273-1281

2021

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans

Gastroenterology (New York, N.Y. 1943), 2006-01, Vol.130 (1), p.44-54

2006

Link zum Volltext

Verfügbarkeit prüfen

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

European journal of endocrinology, 2008-06, Vol.158 (6), p.773

2008

Link zum Volltext

Verfügbarkeit prüfen

Individualised incretin-based treatment for type 2 diabetes

The Lancet (British edition), 2010-08, Vol.376 (9739), p.393-394

2010

Link zum Volltext

Verfügbarkeit prüfen

Studying Pancreatic Risks Caused by Incretin-Based Therapies: Is It a Game? It’s Not a Game

Journal of diabetes science and technology, 2014-07, Vol.8 (4), p.895-897

2014

Link zum Volltext

Verfügbarkeit prüfen

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Incretin Hormone Release Does Not Involve Hepatic Portal Vein Glucose Sensors

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes

Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects

342-P: Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin Glargine

Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability

Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy

Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

Individualised incretin-based treatment for type 2 diabetes

Studying Pancreatic Risks Caused by Incretin-Based Therapies: Is It a Game? It’s Not a Game

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Incretin Hormone Release Does Not Involve Hepatic Portal Vein Glucose Sensors

Aktive Filter

Suchergebnisse filtern